By inducing programmed cell death, the identification of the Fas epitope may eradicate cell evasion. Therefore, focusing on Fas in cancer treatment.
Has the potential to improve the efficacy of existing immunotherapies in addition to aiding in the defeat of therapeutic resistance.
Tushir-Singh told Fox News Digital, “It is clear that off-target killing by Fas is essential to the success of CAR-T therapy.” He continued by saying, “Given the information available,
Researchers and physicians should screen prospective cancer patients who would be receiving CAR-T therapy to check for the comprehensive presence of Fas on their tumors.”
